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Management issues in severe childhood epilepsies 
SHEILA J. WALLACE 
Consultant Paediatric Neurologist, University Hospital of Wales, Heath Park, Cardiff, UK 
The severe epilepsies of childhood are described briefly and information available on the efficacy of newly 
developed antiepileptic drugs (AEDs) in their control is reviewed. Therapeutic advances are awaited for early 
infantile epileptic encephalopathy, early myoclonic encephalopathy, progressive myoclonus epilepsies and 
Kojewnikow syndrome. West syndrome may respond to vigabatrin, and less predictably tolamotrigine. Lamo- 
trigine can be helpful for severe myoclonic epilepsy and myoclonic absences. Astatic seizures may be dramati- 
cally controlled by lamotrigine, whereas vigabatrin may worsen myoclonic attacks. In the Lennox-Gastaut 
syndrome, the efficacy of felbamate has been demonstrated by a controlled trial; vigabatrin and lamotrigine 
can also be helpful. Non-idiopathic partial and secondary generalized epilepsies are responsive to vigabatrin i  
a useful percentage of cases, and some children improve with felbamate, lamotrigine or stiripentol. 
A trial which compares the efficacies of the newer AEDs against each other could provide very useful 
information for the clinician. 
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INTRODUCTION 
In childhood, epilepsies can be usefully divided 
into those in which a good, remitting outcome 
is anticipated; those where a response to ther- 
apy is expected but not inevitable, and where 
continued treatment into adulthood may be 
required; and the severe, resistant forms where 
seizures are likely to persist despite therapy. 
These latter are listed in Table 1. 
Table 1 : Severe childhood epilepsies 
Early infantile pileptic encephalopathy 
Early myoclonic encephalopathy 
Severe myoclonic epilepsy in infants 
Epilepsy with myoclonic absences 
West syndrome--infantile spasms 
Myoclonic-astatic epilepsy 
Lennox-Gastaut syndrome 
Non-idiopathic partial epilepsy, with or without 
secondary generalization 
Progressive myoclonus epilepsies 
Landau-Kleffner syndrome 
Kojewnikow syndrome 
The management of all the severe epilepsies 
includes recognition of cognitive and social dis- 
abilities, as well as, for some children, physical 
handicap. This paper concentrates onthe infor- 
mation currently available on the drug treat- 
ment of severe epilepsies. Much of this comes 
from recently presented work, and some is 
frankly anecdotal, but patterns of response to 
some of the newer antiepileptic drugs (AEDs) 
are beginning to emerge. The information 
available is examined individually for each 
syndrome. Full details of the syndromes con- 
sidered can be found in Roger et al 1. When con- 
trolled, blinded studies are cited, these are 
identified; for all other information the 
patients were being treated in an unblinded 
manner. 
EARLY INFANTILE EPILEPTIC 
ENCEPHALOPATHY 
Frequent onic spasms commence within the 
first few months of life, and are associated with 
suppression-burst on electroencephalograph 
(EEG). Partial seizures can occur but myo- 
clonic attacks are rare. Seizures are intrac- 
table and cognitive development is very 
limited. Early death is not unusual. Occasion- 
ally, adrenocorticotrophic hormone (ACTH) 
may be helpful, but no other AED has been 
found effective. 
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EARLY MYOCLONIC ENCEPHALOPATHY 
Fragmentary myoclonus progressing toerratic 
partial seizures, massive myoclonias, or tonic 
spasms presents before the age of 3 months. 
Suppression-burst characterizes the EEG. 
Severe retardation is invariable and early 
death likely. Neither corticosteroids, ACTH or 
conventional AEDs are effective, but in one 
patient reated personally by the author, there 
was a useful reduction in seizures with lamo- 
trigine. 
SEVERE MYOCLONIC EPILEPSY IN INFANTS 
The seizures tart during the first year of life 
as unilateral or generalized clonic attacks with 
feverish illnesses. Evolution to myoclonic jerks 
and partial seizures occurs in the second year 
of life. Generalized spike or polyspike-waves, 
early photosensitivity and focal abnormalities 
are found on the EEG. Developmental rrest, 
cerebellar and pyramidal signs complicate the 
epilepsy which is resistant o virtually all 
AEDs. Responses to vigabatrin have been 
noted to wear off e. Of three patients personally 
treated with lamotrigine by the author, two 
have had their seizures reduced by more than 
50%, but the third child failed to show any re- 
sponse. Further studies of newer AEDs seem to 
be indicated. 
EPILEPSY WITH MYOCLONIC ABSENCES 
Myoclonic absences, which are associated with 
3 Hz spike-wave on EEG, are accompanied by 
severe bilateral rhythmic jerking, usually of 
the limbs, but the lower face may also be 
involved. Infrequent generalized tonic-clonic 
seizures also occur. Poor cognitive progress is 
usual once the absences commence. 
Response to ethosuximide orvalproate given 
singly is very poor, but some children remit on 
a combination of these two AEDs. Recent ex- 
perience with lamotrigine is encouraging. Of 
six children who had lamotrigine added to 
existing anti-absence drugs, five had more 
than 75% reductions in seizure frequencies, 
and three were seizure-free for several months, 
though relapse later occurred in two 3. Another 
study found a greater than 50% reduction in 
seizures in four out of nine patients given 
lamotrigine 4. Further investigation ofthe effi- 
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cacy of lamotrigine, and the role of concomi- 
tant AED is required. 
WEST SYNDROME 
Infantile spasms, arrest of cognitive develop- 
ment and hypsarrhythmia characterize West 
syndrome. ACTH and steroids were the main- 
stays of treatment for about 20 years. Doses of 
ACTH 20-40 IU/day are reported to be as ef- 
fective as much higher levels '6. Following the 
suggestion that valproate controlled infantile 
spasms ~, this drug has been used mainly at the 
regular dose of 20-30 mg/kg/day. Higher doses, 
up to 100 mg/kg/day, can be more effective, but 
at the expense of thrombocytopenia and muscle 
hypotonia s. Benzodiazepines are likely to 
produce only temporary relief. Appropriate 
doses are clonazepam starting at 0.01-0.03 mg/ 
kg/day or nitrazepam initially 0.5 or 0.1 mg/kg/ 
day 9. High-dose pyridoxal phosphate (30- 
400 mg/day) has been reported to be effective 
in a small percentage of patients l°. Likewise, 
some infants respond to i.v. immunoglobulin 
100-400mg/kg iven at 2-3 weekly inter- 
vals ~ 1,12. 
There seems no doubt hat vigabatrin should 
now be an early choice. The largest study 
relates to 70 children ~3. Forty-seven were aged 
less than 2 years, and the remainder up to 12.5 
years. Thirty-seven had cryptogenic and 33, 
including 14 with tuberous clerosis, sympto- 
matic West syndrome. Vigabatrin dosages 
were 50-150mg/kg/day in older children and 
100-200mg/kg/day in infants. During the 
evaluation phase lasting up to 150 days, of 14 
patients with tuberous clerosis, 10 became 
seizure-free and a further two had a greater 
than 50% reduction in seizures; of another 18 
with symptomatic spasms, six became seizure- 
free and six had a greater than 50% reduction 
in attacks; and in the group of 36 with crypto- 
genic spasms, 12 went into complete remission 
and nine were more than 50% better. During a 
longer-term follow-up there was some loss of 
control, particularly in the cryptogenic group, 
and partial seizures emerged in eight patients, 
of whom six had tuberous clerosis. On the 
whole, vigabatrin seemed less likely to be ef- 
fective if the duration of the illness was more 
than i year. Other reports confirm that vigaba- 
trin can be very useful for control of infantile 
spasms 2,14-~7. The relative efficacies of hydro- 
cortisone and vigabatrin 150 mg/kg/day in the 
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treatment of infantile spasms in tuberous 
sclerosis have been explored Is. Seizures disap- 
peared sooner but relapsed earlier in those 
treated with vigabatrin. 
Lamotrigine can also be effective 4. After 3 
months of lamotrigine, of 13 children treated, 
two were seizure-free and two had a greater 
than 50% reduction in seizures, but the 
remainder were either unchanged or worse. All 
three children treated with felbamate had 
initial reductions in seizures of at least 60%, 
but one relapsed 19. 
MYOCLONIC-ASTATIC EPILEPSY 
Myoclonic, astatic, myoclonic-astatic, absence 
with tonic and clonic components and tonic- 
clonic seizures occur. The EEG initially may be 
normal, but fast spike-waves or polyspike- 
waves are usual. 
Responses to AEDs of each of the seizure 
types listed above, as well as of the complete 
syndrome are considered in this section. Of the 
established rugs, valproate is considered the 
first choice, but no controlled trials have been 
conducted for this or any other therapy. 
Further details about the propensity of vigaba- 
trin to precipitate 14 or  accentuate  4'2°-22 myo- 
clonic seizures have been reported in a single 
case study 23 and in five of a cohort of nine 
patients 2°. Two reports on lamotrigine are at 
variance. In one group, of 13 children with non- 
progressive myoclonias treated with lamotri- 
gine for 3 months, only one had more than 50% 
reduction in seizures and one was more than 
50% worse 4. On the other hand, in a series of 
eight children with myoclonic-astatic epilepsy 
treated with lamotrigine by the author, two 
became seizure-free and a further five had a 
greater than 50% reduction in seizures. All 
those with incomplete control tended to 
relapse, but over periods of up to 3 years over- 
all improvement has been maintained with 
dosage adjustments. 
When children with astatic seizures are con- 
sidered as a group, lamotrigine has been found 
to be very useful 24. Of 17 children tolerant of 
lamotrigine, six became seizure-free and four 
had long-term reduction in seizure frequency. 
A further three had an early response, but 
relapsed and did not come under control with 
dosage adjustments. Felbamate is also re- 
ported to have controlled more than 50% of 
drop attacks in six of 12 children 25. 
LENNOX-GASTAUT SYNDROME 
The main seizure types are tonic-axial, atonic 
and atypical absence, but myoclonic, general- 
ized tonic-clonic or partial attacks may also 
occur. Some of the more recently developed 
AEDs appear promising but longer established 
therapies probably still have a place. Val- 
proate has been the main approach, with 
benzodiazepines, particularly clonazepam or 
nitrazepam contributing to temporary relief. A 
ketogenic diet can produce dramatic results 26 
and intravenous immunoglobulin 27, or thyro- 
tropin-releasing hormone 2s have their advo- 
cates. 
Felbamate is the only drug to have been 
studied with the specific aim of control of 
Lennox-Gastaut syndrome 29. Seventy pa- 
tients participated in a double-blind, placebo- 
controlled, add-on trial. All had multiple 
seizure types and a minimum of 90 atonic or 
atypical absence seizures per month. With an 
age range of 4-36 years (mean 12 years), this 
group is on the whole older than patients 
usually seen in exclusively paediatric prac- 
tices. Carers' diaries were supplemented by 
seizure counts obtained by video-EEG for 4- 
hour periods prior to and at standardized inter- 
vals throughout the trial. Prior to dosing, 
patients later randomized to felbamate had 
higher counts for atonic seizures. Atonic seiz- 
ures occurred in 28 patients randomized to 
felbamate and 22 on placebo. During a main- 
tenance period of 56 days, counts of atonic seiz- 
ures fell by 44% in the felbamate group and 7% 
with placebo (P = 0.002). Total seizure counts, 
as recorded by carers, fell by 26% for felbamate 
and rose by 5% for placebo (P < 0.001) during 
maintenance dosing at 45mg/kg/day. Four 
patients in the felbamate group had no seiz- 
ures of any sort, and five no atonic seizures, 
during maintenance treatment. At the end of 
the double-blind study, 70 patients continued 
in an open-label trial 3°. Total seizures were 
reduced by more than 50% in 21 of 36 subjects 
who converted to felbamate after placebo; 12 of 
22 with atonic seizures were improved by more 
than 50% on conversion to felbamate. The 
results of an investigation of the tolerability 
and greater efficacy of increasing felbamate 
dosage to 60 mg/kg/day are awaited 31. 
The findings with vigabatrin are rather vari- 
able. In an open, add-on, non-controlled trial, 
six out of 26 patients had an excellent result, 
but 13 were either unhelped or worse 17. Of a 
further seven treated in a single-blind, 
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placebo-controlled trial, two had a more than 
50% reduction in seizures, but four were 
worse 22. Other small studies include good re- 
sponses in three of six 2°, one of four 32, 12 of 
2033, one of three 34 and none of six patients 21. 
Beneficial effects tend to wear off with time 2. 
Lamotrigine also shows rather variable 
promise. Of 10 children treated on a com- 
passionate basis or in a single-blind, add-on 
trial, or as part of a pharmacokinetic study, 
three became seizure-free, three improved by 
more than 50% and none were worse 4. In 14 
cases treated by the author, eight had a more 
than 50% improvement, but none became seiz- 
ure-free and one had an increase in seizures. 
Moderate or marked improvement has been re- 
ported in eight of 25 patients treated on a com- 
passionate basis 3s. Two studies which looked 
primarily at adults report good results in 10 of 
1136, and 12 of 27 patients 37. 
NON-IDIOPATHIC PARTIAL EPILEPSIES, 
WITH OR WITHOUT SECONDARY 
GENERALIZATION 
Since, in adults, partial epilepsies are those 
most likely to be resistant o AEDs, the ma- 
jority of new drugs are first examined in this 
context. 
Most reports related to vigabatrin, but there 
is no %lind' study. Scaling-up dose-response 
assessments2O. 3,3s uggest that at least 40 mg/ 
kg/day is needed, although lower doses can be 
effective 39. Most authors use 80-100mg/kg/ 
day, but as much as 175mg/kg/day has been 
given 2. Between one- and two-thirds of 
patients benefit from addition of vigabatrin to 
previous therapy17'2°'21'32'3a'4°'41; but a few 
are made worse 17'2°'41. 
Of 15 children treated with add-on lamotri- 
gine for 3 months, three improved substan- 
tially and one deteriorated4; and of a further 
nine, observed personally, two have improved 
and two deteriorated. 
Two reports, totalling 20 children, suggested 
felbamate can be effective in abolishing or 
reducing partial seizures 25'42. 
A single communication has found that 
three-quarters of children treated with stiri- 
pentol in a single-blind, add-on trial re- 
sponded 43. 
Reports on the use of gabapentin in children 
are awaited. Meanwhile 20-40% improvement 
has been recorded in adults with resistant par- 
tial seizures 44. 
PROGRESSIVE MYOCLONUS EPILEPSIES 
These are usually secondary to biochemically 
definable disorders, such as ceroid lipofusci- 
noses, sialidoses or mitochondrial encephalopa- 
thies; or to Baltic/Mediterranean myoclonus or 
Lafora disease. Valproate continues to be the 
most used AED, but there are anecdotal reports 
of improvement with lamotrigine, particularly 
in ceroid lipofuscinoses. Phenytoin leads to 
worsening in Baltic/Mediterranean myoclonus. 
LANDAU-KLEFFNER SYNDROME 
Acquired aphasia is associated with multi- 
focal spike and spike-wave discharges. Seiz- 
ures, generalized tonic-clonic, partial, or 
atypical absences are infrequent and present 
in 75% of cases. There is a close relationship 
with epilepsy with continuous spike-wave 
during slow sleep. After testing a wide range of 
AEDs, it has been concluded that valproate, 
ethosuximide and benzodiazepines are most 
likely to be effective 4s. There is also consider- 
able support for the use of steroids, initially in 
high dosage and continued over a prolonged 
period at a lower maintenance dose 46. Single 
cases have been improved by lamotrigine. 
KOJEWNIKOW SYNDROME 
Epilepsia partialis continua, not secondary to a 
definable lesion, remains an intractable prob- 
lem. 
UNWANTED EFFECTS OF NEWER AEDS 
Vigabatrin 
The main undesirable features relate to behav- 
iour. Agitation led to discontinuation i about 
5-10% of all cases described. Somnolence was 
sometimes a problem. The worsening of myo- 
clonic seizures recorded by some observers has 
already been noted. 
Lamotrigine 
A sensitivity rash is most likely to occur if 
lamotrigine is added to valproate monotherapy. 
The risk can be minimized by starting lamotri- 
gine at a very low dose (0.02mg/kg/day) and 
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escalating very slowly. Drowsiness and un- 
steadiness may result from high dosage. 
Felbamate 
Anorexia, vomiting and somnolence are re- 
ported. Fatal cases of aplastic anemia and 
hepatic failure now preclude its use in all but 
the most resistant cases. 
Stiripentol 
Anorexia, drowsiness and vomiting may com- 
plicate the use of stiripentol. 
CONCLUSIONS 
For most of the severe epilepsies of childhood, 
the newer AEDs have some beneficial effects in 
some children. On the whole, vigabatrin seems 
better for epilepsies with partial or secondary 
generalized seizures and lamotrigine for those 
of generalized onset. The merits of stiripentol 
and gabapentin are in the early stages of defi- 
nition. A multicentre blind comparison of 
newer AEDs in the treatment of severe epilep- 
tic syndromes of childhood should be con- 
ducted. 
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